MMCAP International Inc. SPC: Form SC 13G - Filed by newsfilecorp.com

SC 13G 1 formsc13g.htm FORM SC 13G MMCAP International Inc. SPC: Form SC 13G - Filed by newsfilecorp.com

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Better Therapeutics Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

08773T104

(CUSIP Number)

July 27, 2023

(Date of Event Which Requires Filing of This Statement)

Check the Appropriate box to designate the rule pursuant to which this schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

CUSIP No. 08773T104

Page 2 of 7 Pages

1	NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
	MMCAP International Inc. SPC

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*			(a) ☑ (b) ☐


3	SEC USE ONLY


4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			0
		6	SHARED VOTING POWER
			3,859,649*
		7	SOLE DISPOSITIVE POWER
			0
		8	SHARED DISPOSITIVE POWER
			3,859,649*
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	3,859,649*

10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			☐


11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
	9.53%**

12	TYPE OF REPORTING PERSON*
	CO

FOOTNOTES

* Consist of 3,859,649 shares of common stock.

** The percentages used herein are calculated based on 40,511,944 shares of common stock outstanding of the Issuer as reported in the Issuer’s Rule 424(b)(5) Prospectus filed with the United States Securities and Exchange Commission on July 26, 2023.

CUSIP No. 08773T104

Page 3 of 7 Pages

1	NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
	MM Asset Management Inc.

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*			(a) ☑ (b) ☐


3	SEC USE ONLY


4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Ontario, Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			0
		6	SHARED VOTING POWER
			3,859,649*
		7	SOLE DISPOSITIVE POWER
			0
		8	SHARED DISPOSITIVE POWER
			3,859,649*
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	3,859,649*

10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			☐


11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
	9.53%**

12	TYPE OF REPORTING PERSON*
	CO

FOOTNOTES

* Consist of 3,859,649 shares of common stock.

CUSIP No. 08773T104

Page 4 of 7 Pages

Item 1 (a). Name of Issuer:

Better Therapeutics, Inc.

Item 1 (b). Address of Issuer's Principal Executive Offices:

548 Market St., #49404, San Francisco, CA, 94101

Item 2 (a). Name of Person Filing:

i) MMCAP International Inc. SPC

ii) MM Asset Management Inc.

Item 2 (b). Address of Principal Business Office or, if None, Residence:

i) c/o Mourant Governance Services (Cayman) Limited

94 Solaris Avenue

Camana Bay, P.O. Box 1348
Grand Cayman, KY1-1108, Cayman Islands

ii) 161 Bay Street
TD Canada Trust Tower Suite 2240
Toronto, ON M5J 2S1 Canada

Item 2 (c). Citizenship:

i) Cayman Islands
ii) Ontario, Canada

Item 2 (d). Title of Class of Securities:

Common Stock, par value $0.0001 per share

Item 2 (e). CUSIP Number:

08773T104

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under Section 15 of the Act;

(b) ☐ Bank as defined in Section 3(a)(6) of the Act;

(d) ☐ Investment Company registered under Section 8 of the Investment Company Act;

(e) ☐ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f) ☐ Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);

(g) ☐ Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);

(h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

CUSIP No. 08773T104

Page 5 of 7 Pages

(i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940:

(j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(j).

☒ If this statement is filed pursuant to Rule 13d-1(c), check this box.

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.

(a) Amount beneficially owned: 3,859,649*

(b) Percent of class: 9.53%**

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote: 3,859,649*

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of: 3,859,649*

* Consist of 3,859,649 shares of common stock.

** The percentages used herein are calculated based on 40,511,944 shares of common stock outstanding of the Issuer as reported in the Issuer's Rule 424(b)(5) Prospectus filed with the United States Securities and Exchange Commission on July 26, 2023.

Instruction. For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

CUSIP No. 08773T104

Page 6 of 7 Pages

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	MMCAP International Inc. SPC

Date: July 31, 2023	By: /s/ Ulla Vestergaard
	Name: Ulla Vestergaard Title: Director


	MM Asset Management Inc.

Date: July 31, 2023	By: /s/ Hillel Meltz
	Name: Hillel Meltz Title: President

CUSIP No. 08773T104

Page 7 of 7 Pages

EXHIBIT 1

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: July 31, 2023

	MMCAP International Inc. SPC

	By: /s/ Ulla Vestergaard
	Name: Ulla Vestergaard Title: Director


	MM Asset Management Inc.

	By: /s/ Hillel Meltz
	Name: Hillel Meltz Title: President

SEC Form SC 13G filed by Better Therapeutics Inc.